secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001493152-21-024422
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa Biosciences begins patient recruitment for Phase I breast cancer vaccine trial
--------------------------------------------------------------------------------

- Patient recruitment commenced Oct 1, 2021 for a preventative breast cancer vaccine developed with Cleveland Clinic and DoD.
- Phase I open-label, dose-escalation trial in triple-negative breast cancer patients at high risk of recurrence.
- Estimated 18–24 participants; trial expected to take approximately one year to complete.
- Vaccine targets alpha-lactalbumin; details at ClinicalTrials.gov identifier NCT04674306.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315221024422/0001493152-21-024422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315221024422/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-024422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer